ReCode Therapeutics said that the Cystic Fibrosis Foundation will provide an additional $3 million for development of RCT2100 inhaled mRNA therapy for CF and that the company has closed a funding of more than $29 million to advance its pipeline. That pipeline includes inhaled therapies for primary ciliary dyskinesia and other lung diseases as well as CF. In September 2023, ReCode announced that it had raised a total of $260 million in Series B funding for development of the inhaled therapies based on its SORT LNP platform.
According to ReCode, the CF Foundation has now committed to a total $33 million investment. The foundation has already provided $15 million for development and Phase 1 trials of RCT2100, the company noted. The additional $3 million from the CFF will go towards a Phase 2 trial of RCT2100 in CF patients who cannot benefit from CFTR modulators.
ReCode Therapeutics CEO Shehnaaz Suliman commented, “With continued support from organizations like the CF Foundation and our collaboration with Praxis, we are building on our momentum to deliver on the promise of genetic medicines for people living with genetic diseases who currently have limited or no effective treatments.”
Read the ReCode Therapeutics press release
